Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Accounts Payables: 2019-2024

Historic Accounts Payables for Fulcrum Therapeutics (FULC) over the last 6 years, with Dec 2024 value amounting to $1.2 million.

  • Fulcrum Therapeutics' Accounts Payables fell 29.32% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year decrease of 29.32%. This contributed to the annual value of $1.2 million for FY2024, which is 57.78% down from last year.
  • Per Fulcrum Therapeutics' latest filing, its Accounts Payables stood at $1.2 million for FY2024, which was down 57.78% from $2.8 million recorded in FY2023.
  • Fulcrum Therapeutics' Accounts Payables' 5-year high stood at $4.8 million during FY2021, with a 5-year trough of $1.2 million in FY2024.
  • Its 3-year average for Accounts Payables is $2.5 million, with a median of $2.8 million in 2023.
  • In the last 5 years, Fulcrum Therapeutics' Accounts Payables soared by 86.60% in 2020 and then tumbled by 57.78% in 2024.
  • Yearly analysis of 5 years shows Fulcrum Therapeutics' Accounts Payables stood at $4.1 million in 2020, then grew by 17.38% to $4.8 million in 2021, then decreased by 24.02% to $3.6 million in 2022, then declined by 24.22% to $2.8 million in 2023, then tumbled by 57.78% to $1.2 million in 2024.